THE BIOMARKER
DISCOVERY COMPANY

CiberMed is a stealth biotechnology company started by industry veterans and Stanford University professors.

Our mission is to be the industry leader in the discovery and measurement of biomarkers using our patented technology which uses novel in silico cell sorting to determine cell proportions and gene expression.

Technologies

Biomarker Discovery

CiberMed applies a variety of data science techniques including machine learning that lead to biomarker discovery. The CiberMed data science team develops biomarker models using immune cell data quantified by iSort™

iSort

iSort™ is a digital cytometry. It quantifies immune cell subsets in silico using gene expression data. The core technology is based on CIBERSORT and CIBERSORTx platforms, that were originally developed at Stanford University, and licensed to CiberMed.

Advantages of iSort

iSort™ digital cytometry provides highly accurate and robust cell subset enumeration from clinical biospecimens.

  • Cost-effective and high-throughput

  • Highly reproducible

  • Unaffected by tissue dissociation

  • Applicable to fresh, frozen, and fixed tissues

  • Applicable to pre-existing gene expression data

Services

Collaboration

User shall select the type(s) of services. Consultations are included.

Run iSort

User to run iSort Fractions and/or Map & Quant locally. iSort Fractions currently offers quantification of 22 immune cell subsets. All other functions implemented in iSort/CIBERSORTx are covered by collaboration.

Map & Quant iSort Fractions
  • Gene expression purification
  • Custom cell types/subsets
Biomarker discovery

Post data analysis

Collaboration
Run iSort
(Self-service)

We currently have numerous collaborations with the pharmaceutical industry for the analysis of clinical data. If you are interested in any of our services, please contact us:

CONTACT US
image-asset

BIOINFORMATICS / DATA SCIENCE

Our team consists of talented and experienced bioinformatics / data scientists from industry and academia (Stanford Medicine).

Publications

About iSortTechnology

Analytical validation of digital cytometry (iSortTM) for leukocyte enumeration using stored blood
Newman, A.M., Nakao, A. et.al. J. Clinical Oncology, 38, 15, Supp. 3452 (2020) (Presented at ASCO)
https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.3542

Analytical validation of iSort™ digital cytometry for leukocyte enumeration in clinical tumor specimens
Newman, A.M., Nakao, A, et.al. J. Clinical Oncology, 38, 15, Supp. e15243 (2020)
https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.e15243

Determining cell type abundance and expression from bulk tissues with digital cytometry
Newman, A.M. et al. Nature Biotechnology 37, 773–782 (2019)
https://pubmed.ncbi.nlm.nih.gov/31061481/

The prognostic landscape of genes and infiltrating immune cells across human cancers
Gentles, A. et al. Nature Medicine 21, 938-945 (2015)
https://pubmed.ncbi.nlm.nih.gov/26193342/

Robust enumeration of cell subsets from tissue expression profiles
Newman, A.M. et al. Nature Methods 12, 453–457 (2015)
https://pubmed.ncbi.nlm.nih.gov/25822800/

iSortapplications

Molecular and immunological signatures are related to clinical benefit from treatment with Vocimagene amiretrorepvec (Toca 511) and 5-fluorocytosine (Toca FC) in patients with glioma
Accomando, W.P. et.al. Clinical Cancer Research (2020)
https://clincancerres.aacrjournals.org/content/early/2020/10/21/1078-0432.CCR-20-0536

iSort™ is based on CIBERSORTx technology. Explore more applications.

MEDIA CONTACT

Meet Our Team

Ashok Krishnamurthi

Ashok Krishnamurthi
CEO and Founder

Ash Alizadeh

Ash Alizadeh
Co-founder

Maximillian Diehn

Max Diehn
Co-founder

Aaron Newman

Aaron Newman
Co-founder

Aki Nakao

Aki Nakao
Sr. Bioinformatics / Data Science Lead,
Head of Data Science

Kathy Li

Kathy Li
Sr. Scientist, Head of Assay Development

Chih Long Liu

Chih Long Liu
Consultant

TEAM BIOS